Screening TCAMS Library for Antimalarial Drug Discovery

Status
On going
Start date
Start stage
Screening
End stage
Screening
Asset
TCAMS (Tres Cantos Antimalarial Set)
Disease
Malaria
Research areas
Drug

GSK will be sharing its Tres Cantos Anti-Malarial Set (TCAMS) compound library with Drs. Audrey Odom John and Paul Hruz at WUSTL for screening for antimalarial drug discovery.

TCAMS, developed as a component of GSK’s research at its Tres Cantos facility, is a diverse set of over 13,500 compounds with activity against blood-stage Plasmodium falciparum, plus associated screening data. GSK shares the TCAMS compounds and data widely to drive antimalarial drug discovery.